Antifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation

Anticancer Research

Volumn 27, Issue 2, 2007, Pages 769-773

  Simon, Marcel ^a   Blatter, Johannes ^b   Granzow, Christof ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Antifolate resistance; Antifolate salvage; CCRF CEM cells; FBS Gold; FCS Gold; Fetal bovine serum; KB cells

Indexed keywords

HYPOXANTHINE; METHOTREXATE; PEMETREXED; THYMIDINE;

ARTICLE; BLOOD ANALYSIS; CELL CULTURE; CELL GROWTH; CELL KINETICS; CELL PROLIFERATION; CYTOTOXICITY; DRUG EFFICACY; PRIORITY JOURNAL;

CELL CULTURE TECHNIQUES; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CULTURE MEDIA; DIALYSIS; DRUG SCREENING ASSAYS, ANTITUMOR; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; HYPOXANTHINE; KB CELLS; LEUKEMIA, T-CELL; METHOTREXATE; SERUM; THYMIDINE;

EID: 34247100722     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Genestier L, Paillot R, Quemeneur L, Izeradjene K and Revillard JP: Mechanisms of action of methotrexate. Immunopharmacol 47: 247-257, 2000.
2. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M and Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116-1123, 1997.
3. Kinsella AR, Smith D and Pickard M: Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75: 935-945, 1997.
4. Sobrero AF and Bertino JR: Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum. Int J Cell Cloning 4: 51-62, 1986.
5. de Anta JM, Real FX and Mayol X: Low tumor cell density environment yields survival advantage of tumor cells exposed to MTX in vitro. Biochim Biophys Acta 1721: 98-106, 2005.
6. Heuser M, Kopun M, Rittgen W and Granzow C: Cytotoxicity determination without photochemical artifacts. Cancer Lett 223: 57-66, 2005.
7. Evege EK, Nash CR, Bodziak ML and Jayme DW: Alternative serum substitutes for fetal bovine serum. J Cell Biol 101: 489a, 1985.
8. Bodziak ML, Grefrath PL, Price PJ and Jayme DW: Mammalian cell proliferation in low serum medium. In Vitro Cell Dev Biol 21: 47A (abstract no. 146), 1985.
9. Barnes D and Sato G: Methods for growth of cultured cells in serum-free medium. Anal Biochem 102: 255-270, 1980.
10. Foetal Calf Serum Gold, Product Sheet. PAA Laboratories GmbH, Haidmannweg 9, A-4061 Pasching, Austria. http:// www.paa.at
11. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, Barredo J, Jannatipour M and Moran RG: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35: 4450-4454, 1992.
12. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C and Dempsey JA: Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26: 68-73, 1999.
13. Miwa T, Hitaka T, Akimoto H and Nomura H: Novel pyrrolo[2,3-d]pyrimidine antifolates: synthesis and antitumor activities. J Med Chem 34: 555-560, 1991.
14. Gangjee A, Vidwans A, Elzein E, McGuire JJ, Queener SF and Kisliuk RL: Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines. J Med Chem 44: 1993-2003, 2001.